文献速递脑血管病

血清Netrin-1升高与缺血性卒中预后改善相关

Increased Serum Netrin-1 Is Associated With Improved Prognosis of Ischemic Stroke.
PubMed 文献 · Stroke · 2019-01-01

本研究基于CATIS试验的3346例缺血性卒中患者,检测基线血清Netrin-1水平并随访3个月。结果显示,校正混杂因素后,血清Netrin-1升高与死亡或主要残疾风险降低独立相关,且呈线性剂量反应关系,提示其可能作为预后生物标志物。

要点

  • 血清Netrin-1每升高1个SD(对数转换),主要结局风险降低17%。
  • 最高与最低四分位比较,主要结局OR为0.65(95%CI 0.47-0.88)。
  • 将Netrin-1四分位加入常规风险因素模型可改善风险预测。

核心结论

  • 血清Netrin-1升高与缺血性卒中3个月预后改善独立相关,可能作为潜在预后生物标志物。

研究设计与样本

  • 基于CATIS试验的回顾性队列分析,纳入3346例缺血性卒中患者,检测基线血清Netrin-1并随访3个月。

主要发现

  • 随访3个月,845例(25.25%)发生死亡或主要残疾。
  • 校正基线NIHSS评分及其他混杂因素后,Netrin-1最高与最低四分位比较,主要结局OR为0.65(95%CI 0.47-0.88;Ptrend=0.002)。
  • 对数转换Netrin-1每升高1个SD,主要结局风险降低17%(95%CI 7%-26%)。
  • 样条回归显示Netrin-1与主要结局风险呈负性线性剂量反应关系(Plinearity=0.003)。
  • 将Netrin-1四分位加入常规风险因素模型,净重分类改善指数为14.74%(P=0.002),综合判别改善指数为0.40%(P=0.005)。

关键数值与推荐

  • 主要结局定义为卒中后3个月内死亡和主要残疾(改良Rankin量表评分≥3)的复合终点。

临床怎么用

  • 血清Netrin-1或可作为缺血性卒中早期预后评估的参考指标,但尚需外部样本验证。

局限性

  • 研究基于CATIS试验人群,结论外推需谨慎;需其他缺血性卒中样本重复验证并阐明潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Previous experimental studies suggested that serum netrin-1 was associated with the progression of ischemic stroke. Knowledge about netrin-1 among ischemic stroke patients may provide new ideas for the prognostic assessment of ischemic stroke. The aim of this study was to investigate the association between serum netrin-1 and prognosis of ischemic stroke. Methods- Serum netrin-1 levels at baseline were measured for 3346 ischemic stroke patients from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke), and all patients were followed up at 3 months after stroke onset. The primary outcome was a combination of death and major disability (modified Rankin Scale score of ≥3) within 3 months after stroke onset. Results- Up to 3 months after stroke onset, 845 patients (25.25%) experienced death or major disability. After adjustment for baseline National Institutes of Health Stroke Scale score and other potential confounders, elevated serum netrin-1 was associated with a decreased risk of primary outcome (odds ratio, 0.65; 95% CI, 0.47-0.88; Ptrend=0.002) when 2 extreme quartiles were compared. Each SD increase of log-transformed netrin-1 was associated with 17% (95% CI, 7%-26%) decreased risk of primary outcome. Multivariable-adjusted spline regression models showed a negative linear dose-response relationship between serum netrin-1 and the risk of primary outcome ( Plinearity=0.003). Adding netrin-1 quartile to a model containing conventional risk factors improved risk prediction for primary outcome (net reclassification improvement index =14.74%; P=0.002; integrated discrimination improvement =0.40%; P=0.005). Conclusions- Elevated serum netrin-1 levels were associated with improved prognosis at 3 months after ischemic stroke, suggesting that serum netrin-1 may be a potential prognostic biomarker for ischemic stroke. Further studies from other samples of ischemic stroke patients are needed to replicate our findings and to clarify the potential mechanisms. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01840072.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Guo D, Zhu Z, Zhong C, et al. Increased Serum Netrin-1 Is Associated With Improved Prognosis of Ischemic Stroke. Stroke. 2019. PMID: 30852966. doi:10.1161/STROKEAHA.118.024631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。